Vivani Medical reports positive Phase 1 data for NPM-115 implant and prioritizes semaglutide implant NPM-139

Vivani Medical, Inc.

Preliminary Q2 2025 cash and cash equivalents $6.8M, plus $11.25M committed capital through March 2026.
LIBERATE-1 Phase 1 study of NPM-115 (exenatide implant) met primary safety and PK objectives; no serious adverse events.
Preclinical data for NPM-139 (semaglutide implant) showed ~20% weight loss maintained over 231 days from a single implant.
Vivani prioritizes NPM-139 for clinical development, with IND submission planned and clinical start expected in 2026.
Semaglutide products (Ozempic, Wegovy, Rybelsus) generated over $29B in 2024 sales, supporting prioritization.

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.